Genetically Engineered Fusion Proteins for Anti-angiogenesis
발표자
()
초록
내용
Genetically engineered fusion proteins for anti-angiogenesis have been of growing interest to treat uncontrolled neovascularization. We are interested in elastin-based polypeptide (EBPs) as thermo-responsive biopolymers with reversible phase transition, and their fusions with functional peptides to control biological phenomena at cell level. Herein, we report stimuli responsive EBP fusion proteins with the anti-angiogenic peptides (APs) in the form of soluble monomers, which can bind to the cell receptors and trigger cellular signaling for anti-angiogenesis. These fusion proteins with four different EBP block lengths showed lower critical solution temperature (LCST) behavior, and the LCSTs were finely controlled by the EBP block length. The anti-angiogenesis function was studied in vitro by human umbilical vein endothelial cells tubing assay depending on EBP block lengths. Potentially, these fusion proteins with the AP moieties would be useful as biodrugs to treat neovascularization.